1. Home
  2. JFIN vs AVXL Comparison

JFIN vs AVXL Comparison

Compare JFIN & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JFIN
  • AVXL
  • Stock Information
  • Founded
  • JFIN 2011
  • AVXL 2004
  • Country
  • JFIN China
  • AVXL United States
  • Employees
  • JFIN N/A
  • AVXL N/A
  • Industry
  • JFIN Finance: Consumer Services
  • AVXL Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • JFIN Finance
  • AVXL Health Care
  • Exchange
  • JFIN Nasdaq
  • AVXL Nasdaq
  • Market Cap
  • JFIN 969.7M
  • AVXL 794.0M
  • IPO Year
  • JFIN 2019
  • AVXL N/A
  • Fundamental
  • Price
  • JFIN $14.86
  • AVXL $12.13
  • Analyst Decision
  • JFIN
  • AVXL Strong Buy
  • Analyst Count
  • JFIN 0
  • AVXL 2
  • Target Price
  • JFIN N/A
  • AVXL $44.00
  • AVG Volume (30 Days)
  • JFIN 106.5K
  • AVXL 1.2M
  • Earning Date
  • JFIN 08-26-2025
  • AVXL 08-05-2025
  • Dividend Yield
  • JFIN 5.38%
  • AVXL N/A
  • EPS Growth
  • JFIN 2.88
  • AVXL N/A
  • EPS
  • JFIN 3.43
  • AVXL N/A
  • Revenue
  • JFIN $840,800,386.00
  • AVXL N/A
  • Revenue This Year
  • JFIN N/A
  • AVXL N/A
  • Revenue Next Year
  • JFIN N/A
  • AVXL N/A
  • P/E Ratio
  • JFIN $4.34
  • AVXL N/A
  • Revenue Growth
  • JFIN 4.83
  • AVXL N/A
  • 52 Week Low
  • JFIN $4.00
  • AVXL $4.93
  • 52 Week High
  • JFIN $19.23
  • AVXL $14.44
  • Technical
  • Relative Strength Index (RSI)
  • JFIN 36.37
  • AVXL 62.32
  • Support Level
  • JFIN $15.73
  • AVXL $10.98
  • Resistance Level
  • JFIN $16.85
  • AVXL $13.99
  • Average True Range (ATR)
  • JFIN 0.87
  • AVXL 0.71
  • MACD
  • JFIN -0.36
  • AVXL 0.11
  • Stochastic Oscillator
  • JFIN 31.91
  • AVXL 54.41

About JFIN Jiayin Group Inc.

Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

Share on Social Networks: